Burning Rock Biotech Limited reiterated revenue guidance for the full year 2023. For the period, the company expects revenue guidance of approximately 20% growth over 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.325 USD | +3.67% | +4.98% | -10.48% |
04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M | MT |
04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90 | MT |
1st Jan change | Capi. | |
---|---|---|
-10.48% | 82.38M | |
-16.99% | 8.67B | |
+64.83% | 4.25B | |
-1.10% | 2.51B | |
-10.68% | 2.47B | |
-41.76% | 2.25B | |
-9.12% | 1.91B | |
-19.68% | 1.56B | |
-39.61% | 1.19B | |
+9.54% | 1.15B |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Burning Rock Biotech Limited Reiterates Revenue Guidance for the Full Year 2023